Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > REGULATORY
REGULATORY
- MHLW to Request Budgets for AMED’s Project to Promote Commercialization of Innovative Medical Seeds
July 15, 2016
- More Companies Interested in Supporting Academia Research from the Seeds Stage: AMED Official
July 14, 2016
- MHLW to Set Prerequisites for Patients, Physicians to Optimize Innovative Drug Use: Pharma Bureau Chief
July 13, 2016
- Despite Brexit, Importance of UK “Will Remain Unchanged”: Dr Suematsu of AMED
July 12, 2016
- AMED Aims to Facilitate Drug Makers’ Access to Knowledge at Research Institutions: President
July 12, 2016
- PMDA Inks Comprehensive Collaboration Accord with NCNP
July 12, 2016
- MHLW to Put Expensive Drug Issue Up for Chuikyo Discussion ASAP: Medical Economics Division Chief
July 11, 2016
- “New Rules” for Expensive Drugs Could Impact Business Models: Health Insurance Bureau Chief
July 8, 2016
- Number of Academia-Originated Drugs Highest in Oncology: AMED Survey
July 7, 2016
- Imusera/Gilenya Don’t Delay Disability Progression in Primary Progressive MS, MHLW Orders Label Revisions
July 6, 2016
- MHLW OKs Sanofi’s PCSK9 Inhibitor, Other Drugs
July 5, 2016
- MHLW to Issue “Blue Book” on Quality of Generics by March-End
July 1, 2016
- It’s Now Up to UK Govt to Decide on Future Action after Brexit Vote: EMA Spokesperson
June 30, 2016
- MHLW Begins Interim Review of 10-Year Strategy on Hepatitis Research
June 29, 2016
- MHLW Restresses Risk of HBV Reactivation for 8 Hep C Drugs
June 29, 2016
- Key Govt Panel Meets to Discuss Brexit’s Impact on Industries
June 29, 2016
- AMED Sets Up First Overseas Outpost in Singapore
June 28, 2016
- MHLW Vows to Forge Ties with UK Counterpart in Post-Brexit Regulations
June 27, 2016
- JEC Rengo Petitions MHLW to Eliminate “Huge-Seller” Repricing in Its Policy Proposal
June 27, 2016
- Panel to Discuss Zoster Vaccine’s Add’l Use, DPT Vaccine’s Booster Dose for Public Immunization Program
June 24, 2016
ページ
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Adeno-associated virus (AAV) gene therapies have long been viewed as carrying only a minimal risk of insertional mutagenesis — a…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…